COVID-19 triggers huge rise in donations for research
The COVID-19 outbreak at the beginning of 2020 sparked a huge rise in private philanthropic giving by billionaires and big private company charitable foundations in China with a substantial amount going towards research and development of vaccines, antiviral drugs and other treatments being developed by teams of scientists throughout China but particularly at elite universities and research centres.
A research report on
Pandemic Philanthropy in China by Bridge Consulting’s Beijing Office calculated that some CNY1.8 billion (US$279 million) was contributed to research and development (R&D) in China in the first half of 2020 after a strict lockdown was declared on 23 January 2020 in Wuhan, where the virus is thought to have originated.
COVID-19 survivors can show persistent symptoms six months after recovery, study finds
Viral infections are self-limiting. When the body’s immune system has won over the battle, the body is expected to shortly recover. However, many convalescents from the coronavirus disease 2019 (COVID-19) experience persistent symptoms that can last for months.
Called “long haulers” these individuals experience a variety of symptoms, such as the difficulty of breathing, a cough, and fatigue.
Now, researchers at the Wuhan Research Center for Communicable Disease Diagnosis and Treatment, the Chinese Academy of Medical Sciences in China revealed that some patients who had recovered from COVID-19 are experiencing symptoms that persisted for more than six months.
KUALA LUMPUR Malaysian Prime Minister Muhyiddin Yassin said Monday that his country will start its first phase 3 clinical trials of COVID-19 vaccines which i
Share this article
Share this article
SAN FRANCISCO and SUZHOU, China, Jan. 11, 2021 /PRNewswire/ Innovent Biologics, Inc. ( Innovent , HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced with Eli Lilly and Company ( Lilly ,NYSE: LLY) that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection) as second-line therapy for squamous non-small cell lung cancer (sqNSCLC). The application is the third sNDA for TYVYT® (sintilimab injection) in NSCLC.
This sNDA was based on a randomized, open-label, Phase 3 clinical trial (ORIENT-3) evaluating TYVYT® (sintilimab injection) as second-line therapy for patients with advanced or recurrent sqNSCLC whose cancer had progressed on first-line platinum-based chemotherapy. Based on the
Malaysia regulators approve phase 3 trials of Chinese-manufactured COVID-19 vaccine - World News sina.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com Daily Mail and Mail on Sunday newspapers.